Comparison of Efficacy of Topical Westerhoff Formula Cream Vs Topical 4% Hydroquinone for the Treatment of Melasma

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07508098

Enrollment

Registered

2026-04-02

Start date

2025-07-18

Completion date

2026-01-19

Last updated

2026-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma (Facial Melasma)

Keywords

MASI. Melasma. Westerhoff formula. 4 % Hydroquinone

Brief summary

study was conducted on middle aged male and female, including families and health care professional also.

Interventions

DRUGTriple combination cream

4.7% N-acetylcysteine, 2% Hydroquinone and 0.1 % triamcinolone acetate twice daily for 8 weeks

DRUGHydroquinone 4% Cream

twice daily for 8 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Intervention model description

participants will be assigned to two parallel groups receiving either triple combination therapy or 4% hydroquinone cream and outcome will be compared between groups

Eligibility

Sex/Gender

ALL

Age

15 Years to 45 Years

Healthy volunteers

Inclusion criteria

* patient with facial melasma of age between 15 years to 45 years of both gender

Exclusion criteria

* patient who have already taken treatment within 8 weeks, pregnant women, who are taking hormonals therapy and patient of dementia

Design outcomes

Primary

Measure	Time frame	Description
proportion of participants achieving 60% reduction in the melasma area severity index (MASI-60)	8 weeks	the primary outcome is the proportion of the participants achieving 60% reduction in MASI score from baseline after 8 weeks of treatment. MASI is the scoring system used to assess the melasma on the basis of severity darkness and the homogeneityenicity
proportion of participants achieving >60% reduction in Melasma Area and severity index (MASI-60)	baseline to 8 weeks	The primary outcome is the proportion of the participants achieving 60% reduction in MASI Score rom the baseline after treatment. MASI is the scoring system used to assess the severity of melasma based on the area, darkness nd the homogeneity

Countries

Pakistan

Contacts

STUDY_DIRECTORQAMMAR khan DR, MBBS. FCPS(Dermatalogy)

Pak Emirates Military Hospital

STUDY_CHAIRMoizza tHAIR Dr, MBBS.FCPS(Dermatology)